Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses phase 2 Study of pembro plus platinum doublet chemotherapy and radiotherapy as first-line therapy for locally advanced NSCLC presented at this year’s virtual ASCO.
Salma Jabbour, MD on Phase 2 Study of Pembrolizumab plus Platinum Doublet Chemotherapy in NSCLC @SalmaJabbour1 @RutgersCancer #ASCO2020
By Editor